Clinical trial · Observational
Establish Diagnostic Models Based on Portal Venous Blood for Pancreatic Cancer
Establish a Diagnostic Model Based on Multiple Molecule Profiling and Certain Established Markers for Identification of Pancreatic Cancer
NCT04536220CI-TRIAL-00075532unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Explore new markers based on portal venous blood sampling to establish novel diagnostic models for identification of malignant pancreatic mass.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Diagnoses Disease | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Endoscopic Ultrasound (EUS), Fine Needle Aspiration | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- pancreatic mass diagnosed benign
- description
- Through pathological examination, radiological examination and follow-up, these patients are finally diagnosed with benign pancreatic mass.
- interventionNames
- Diagnostic Test: Endoscopic Ultrasound (EUS), Fine Needle Aspiration
- label
- pancreatic mass diagnosed malignant
- description
- Through pathological examination, radiological examination and follow-up, these patients are finally diagnosed with pancreaitic cancer.
- interventionNames
- Diagnostic Test: Endoscopic Ultrasound (EUS), Fine Needle Aspiration
Primary outcomes (1)
- measure
- Status of survival
- timeFrame
- through study completion, an average of 1 year
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. age 18-75 years,male or female 2. diagnosis or suspection of solid pancreatic mass based on previous imaging examination (ultrasonography, CT or MRI) 3. lesion diameter larger than 1 cm 4. signed informed consent letter Exclusion Criteria: 1. pregnant female 2. Pancreatic cystic lesions 3. Anticoagulant/antiplatelet therapy cannot be suspended 4. unable or refuse to provide informed consent 5. Coagulopathy (platelet count \< 50× 103/μL,international normalized ratio \> 1.5) 6. Severe cardiopulmonary dysfunction that cannot tolerate intravenous anesthesia 7. with history of mental disease 8. other medical conditions that are not suitable for EUS-FNA
References
Publications (0)
Data not yet available
No reference posted for this study.